Baseline immunity to SARS-CoV-2 (COVID-19) in the German population.

Baseline immunity to SARS-CoV-2 (COVID-19) in the German population. - GUIDE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00029693

Enrollment

16500

Registered

2022-07-19

Start date

2022-07-29

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID19 U07.1

Interventions

Group 1: Participants will be asked once about risk factors for severe courses of SARS-CoV-2 infection and their vaccination and recovery status. Subsequently, a set for collecting a blood sample from

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Randomised invitation based on participation in the payback panel - Randomised invitation for participation via telephone - Ability to answer a questionaire in german

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the prevalence of anti-SARS/CoV-2 seropositive individuals in the study population, defined as the number of individuals with positive laboratory findings for S or N antibodies divided by the total number of study participants.	—

Secondary

Measure	Time frame
Secondary endpoints are. (i) the "underdetection rate", defined as the number of individuals with a positive laboratory result (in the study) but without known prior exposure to SARS-CoV-2 (before the study was conducted), divided by the total number of study participants, (ii) the "vaccination underreporting rate," defined as the difference between the publicly reported vaccination rate and the study vaccination rate, which is the ratio of the reported vaccinations in the questionnaire to the total number of study participants.	—

Measure

Time frame

Secondary endpoints are. (i) the "underdetection rate", defined as the number of individuals with a positive laboratory result (in the study) but without known prior exposure to SARS-CoV-2 (before the study was conducted), divided by the total number of study participants, (ii) the "vaccination underreporting rate," defined as the difference between the publicly reported vaccination rate and the study vaccination rate, which is the ratio of the reported vaccinations in the questionnaire to the total number of study participants.

—

Countries

Germany

Contacts

Public ContactHendrik Streeck

Institut für Virologie/Universitätsklinikum Bonn

virologie@ukbonn.de022828715522

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026